Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 15% in early trading, driven by the upcoming IPO on the STAR Market and a recent partnership with Merck for antibody development [1] Group 1: IPO Details - Baiaosaitu plans to raise 1.185 billion yuan through its STAR Market IPO, with funds allocated for early drug development services, antibody drug research, preclinical and clinical research projects, and to supplement working capital [1] - The IPO review is scheduled for September 24, marking a critical milestone for the company [1] Group 2: Partnership with Merck - Earlier this month, Baiaosaitu signed an evaluation agreement with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice platform for Merck to assess their feasibility for antibody-conjugated lipid nanoparticle formulations [1] - Merck has been granted exclusive rights to acquire selected antibody assets, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing royalties [1]

值得注意的是，本月初，据百奥赛图官微消息，公司与全球领先的科技公司默克(Merck)已签署一项抗 体选择权的评估协议，推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米 颗粒(LNP)。根据协议条款，百奥赛图将提供基于其RenMice®平台自主开发的全人抗体，由默克评估将 其用于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权，百奥赛图有 权获得相应的费用付款及销售分成和再许可分成。 智通财经APP获悉，百奥赛图-B(02315)早盘涨超15%，截至发稿，涨11.41%，报27.74港元，成交额 1202.64万港元。 消息面上，9月17日，上交所上市审核委员会发布公告，百奥赛图的科创板IPO迎来关键节点，首发事 项将于9月24日接受审议。此次科创板IPO，百奥赛图计划募集资金11.85亿元，募集资金将投向药物早 期研发服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目、补充流动资金。 ...